Corrections & Amplifications This headline was corrected at 0533 GMT to reflect it should be Sandoz, not Sadoz By Cecilia Butini Novartis AG on Tuesday posted declining earnings and sales Read more
Tag: Novartis
Novartis hemoglobinuria trial meets two primary endpoints
Novartis AG NOVN, +0.47% NVS, +2.05% said Monday that a study on a drug to treat adult paroxysmal nocturnal hemoglobinuria, a red blood cell condition, has met its two primary Read more
Novartis to spin off, list Sandoz business
Novartis AG is planning to spin off its generics-and-biosimilars division Sandoz and list it as a standalone company in Switzerland, a move that will enable Novartis to focus on innovative Read more
Novartis sales and profit drop, but backs 2022 guidance
Corrections & Amplifications This headline was corrected at 0516 GMT becuase the core oper income was misstated as $2.23B. Novartis AG said its sales and profit fell in the second Read more
Dow Jones Newswires: Novartis sales and profit drop, but backs 2022 guidance
The Swiss pharmaceutical company on Tuesday posted net profit of $1.69 billion, down from $2.89 billion a year earlier.